SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Daizhong Liu, Aixiang Liu, Junping Peng, Yong Hu, Xielin Feng, Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib, European Journal of Medical Research, 2015, 20, 1, 12

    CrossRef

  2. 2
    Toshihiro Kitajima, Etsuro Hatano, Yusuke Mitsunori, Kojiro Taura, Yasuhiro Fujimoto, Masaki Mizumoto, Hideaki Okajima, Toshimi Kaido, Sachiko Minamiguchi, Shinji Uemoto, Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection, Clinical Journal of Gastroenterology, 2015,

    CrossRef

  3. 3
    Christine C Hsu, Abhishek Goyal, Alina Iuga, Saravanan Krishnamoorthy, Valerie Lee, Elizabeth C Verna, Shuang Wang, Fei-Na Chen, Rosa Rodriguez, Jean Emond, Paul Berk, Jay Lefkowitch, Lorna Dove, Robert S Brown, Abby B Siegel, Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients, Clinical and Translational Gastroenterology, 2015, 6, 2, e74

    CrossRef

  4. 4
    Taiga Otsuka, Shunya Nakashita, Kimihiko Yanagita, Keisuke Ario, Hiroaki Kawasoe, Seiji Kawazoe, Yuichiro Eguchi, Toshihiko Mizuta, Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib, Diseases, 2015, 3, 2, 68

    CrossRef

  5. 5
    Luigi Bolondi, Antonio Craxi, Franco Trevisani, Bruno Daniele, Giovan Giuseppe Di Costanzo, Stefano Fagiuoli, Calogero Cammà, Paolo Bruzzi, Romano Danesi, Federico Spandonaro, Corrado Boni, Armando Santoro, Massimo Colombo, Refining sorafenib therapy: lessons from clinical practice, Future Oncology, 2015, 11, 3, 449

    CrossRef

  6. 6
    Giovan Giuseppe Di Costanzo, Giorgio de Stefano, Raffaella Tortora, Nunzia Farella, Luigi Addario, Filippo Lampasi, Alfonso Galeota Lanza, Gabriella Cordone, Michele Imparato, Nicola Caporaso, Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma, Future Oncology, 2015, 11, 6, 943

    CrossRef

  7. 7
    Rodolfo Sacco, Assessment of radiologic response to targeted therapies in patients with hepatocellular carcinoma, Future Oncology, 2014, 10, 13, 2073

    CrossRef

  8. 8
    Kaoru Tsuchiya, Yasuhiro Asahina, Shuya Matsuda, Masaru Muraoka, Toru Nakata, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Shoko Suzuki, Takanori Hosokawa, Takashi Nishimura, Ken Ueda, Teiji Kuzuya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto, Namiki Izumi, Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma, Cancer, 2014, 120, 2
  9. 9
    Satoshi Shiba, Takuji Okusaka, Masafumi Ikeda, Hidetsugu Saito, Takafumi Ichida, Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib, Hepatology Research, 2014, 44, 13
  10. 10
    Suguru Yamada, Norio Okumura, Lan Wei, Bryan C. Fuchs, Tsutomu Fujii, Hiroyuki Sugimoto, Shuji Nomoto, Shin Takeda, Kenneth K. Tanabe, Yasuhiro Kodera, Epithelial to Mesenchymal Transition is Associated with Shorter Disease-Free Survival in Hepatocellular Carcinoma, Annals of Surgical Oncology, 2014, 21, 12, 3882

    CrossRef

  11. 11
    Yu-Yun Shao, Ming-Chih Ho, Ann-Lii Cheng, Chih-Hung Hsu, Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases, Journal of the Formosan Medical Association, 2014, 113, 8, 577

    CrossRef

  12. 12
    Omar Abdel-Rahman, Manal Abdelwahab, Mohammed Shaker, Sherif Abdelwahab, Mohammed Elbassiony, Mahmoud Ellithy, Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience, Journal of the Egyptian National Cancer Institute, 2014, 26, 1, 9

    CrossRef

  13. 13
    Marcus Alexander Wörns, Peter Robert Galle, Sorafenib for the treatment of hepatocellular carcinoma, Hepatic Oncology, 2014, 1, 2, 189

    CrossRef

  14. 14
    Cheng-Hung Chien, Rong-Nan Chien, Thalidomide induces complete remission of advanced hepatocellular carcinoma, Advances in Digestive Medicine, 2014, 1, 2, 64

    CrossRef

  15. 15
    Maria Varela, Olegario Castaño-Fernández, Marcelo Garrido, Lorena Blanco-García, Pablo Martínez-Camblor, Alicia Mesa-Álvarez, Carmen Navascués, Valle Cadahía-Rodrigo, Rafael Menéndez de Llano, Ramon Pérez-Álvarez, Maria Luisa González-Diéguez, Manuel Rodríguez, Time to Progression of AFP (TPA) as a Predictor of Survival in Hepatocellular Carcinoma Treated with Sorafenib (SOR), Journal of Cancer Therapy, 2014, 05, 14, 1332

    CrossRef

  16. 16
    Seiji Oguro, Satoshi Nara, Shunsuke Kondo, Shutaro Hori, Yoji Kishi, Minoru Esaki, Kazuaki Shimada, Tomoo Kosuge, Takuji Okusaka, Hidenori Ojima, A Case of Pathological Complete Response after Combination Chemotherapy by Sorafenib and Cisplatin Hepatic Arterial Infusion for an Advanced Hepatocellular Carcinoma, The Japanese Journal of Gastroenterological Surgery, 2013, 46, 12, 915

    CrossRef

  17. 17
    Yu-Yun Shao, Po-Chin Liang, Yao-Ming Wu, Chun-Chieh Huang, Kai-Wen Huang, Jason C. Cheng, Chih-Hung Hsu, Chiun Hsu, Ann-Lii Cheng, Zhong-Zhe Lin, A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy, Liver International, 2013, 33, 9
  18. 18
    Rodolfo Sacco, Lorenzo Faggioni, Irene Bargellini, Barbara Ginanni, Valentina Battaglia, Antonio Romano, Marco Bertini, Giampaolo Bresci, Carlo Bartolozzi, Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: Results of a pilot study, Digestive and Liver Disease, 2013, 45, 9, 776

    CrossRef

  19. 19
    Kerstin Schütte, Matthias Kipper, Stefan Kahl, Jan Bornschein, Tobias Götze, Daniela Adolf, Jörg Arend, Ricarda Seidensticker, Hans Lippert, Jens Ricke, Peter Malfertheiner, Clinical Characteristics and Time Trends in Etiology of Hepatocellular Cancer in Germany, Digestion, 2013, 87, 3, 147

    CrossRef

  20. 20
    Ju-Yeon Cho, Yong-Han Paik, Ho Yeong Lim, Young Gon Kim, Hyo Keun Lim, Yang Won Min, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma, Liver International, 2013, 33, 6
  21. 21
    Takahide Nakazawa, Hisashi Hidaka, Juichi Takada, Yusuke Okuwaki, Yoshiaki Tanaka, Masaaki Watanabe, Akitaka Shibuya, Tsutomu Minamino, Shigehiro Kokubu, Wasaburo Koizumi, Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib, European Journal of Gastroenterology & Hepatology, 2013, 25, 6, 683

    CrossRef

  22. 22
    Sadahisa Ogasawara, Fumihiko Kanai, Yoshihiko Ooka, Tenyu Motoyama, Eiichiro Suzuki, Akinobu Tawada, Tetsuhiro Chiba, Osamu Yokosuka, Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma, Hepatology International, 2013, 7, 2, 703

    CrossRef

  23. 23
    Takuji Torimura, Hideki Iwamoto, Toru Nakamura, Hironori Koga, Takato Ueno, Robert S. Kerbel, Michio Sata, Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma, Translational Oncology, 2013, 6, 5, 511

    CrossRef

  24. 24
    Kornelius Schulze, Christin Gasch, Katharina Staufer, Björn Nashan, Ansgar W. Lohse, Klaus Pantel, Sabine Riethdorf, Henning Wege, Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma, International Journal of Cancer, 2013, 133, 9
  25. 25
    Yong Kang Lee, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang Hun Lee, Do Yun Lee, Kwang-Hyub Han, Chae Yoon Chon, Jun Yong Park, Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization, BMC Cancer, 2013, 13, 1, 5

    CrossRef

  26. 26
    Anne Helene Køstner, Morten Sorensen, René Krøjgaard Olesen, Henning Grønbæk, Ulrik Lassen, Morten Ladekarl, Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability, The Scientific World Journal, 2013, 2013, 1

    CrossRef

  27. 27
    Quirino Lai, Fabio Melandro, Rafael S. Pinheiro, Andrea Donfrancesco, Bashir A. Fadel, Giovanni B. Levi Sandri, Massimo Rossi, Pasquale B. Berloco, Fabrizio M. Frattaroli, Alpha-Fetoprotein and Novel Tumor Biomarkers as Predictors of Hepatocellular Carcinoma Recurrence after Surgery: A Brilliant Star Raises Again, International Journal of Hepatology, 2012, 2012, 1

    CrossRef

  28. 28
    Julien Edeline, Eveline Boucher, Yan Rolland, Elodie Vauléon, Marc Pracht, Christophe Perrin, Catherine Le Roux, Jean-Luc Raoul, Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma, Cancer, 2012, 118, 1
  29. 29
    Allison M. Given, Pamela M. Whalen, Peter J. O’Brien, Chad A. Ray, Development and validation of an alpha fetoprotein immunoassay using Gyros technology, Journal of Pharmaceutical and Biomedical Analysis, 2012, 64-65, 8

    CrossRef

  30. 30
    Yu-Yun Shao, Zhong-Zhe Lin, Chiun Hsu, Kuan-Der Lee, Chi-Huang Hsiao, Yen-Shen Lu, Chien-Chung Huang, Yin-Chun Shen, Chih-Hung Hsu, Ann-Lii Cheng, Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma, Oncology, 2012, 82, 1, 59

    CrossRef

  31. 31
    Kenichiro Enooku, Ryosuke Tateishi, Fumihiko Kanai, Yuji Kondo, Ryota Masuzaki, Tadashi Goto, Shuichiro Shiina, Haruhiko Yoshida, Masao Omata, Kazuhiko Koike, Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times, Journal of Gastroenterology, 2012, 47, 1, 71

    CrossRef

  32. 32
    Shuichi Kaneko, Junji Furuse, Masatoshi Kudo, Kenji Ikeda, Masao Honda, Yasunari Nakamoto, Morikazu Onchi, Goshi Shiota, Osamu Yokosuka, Isao Sakaida, Tetsuo Takehara, Yoshiyuki Ueno, Kazumasa Hiroishi, Shuhei Nishiguchi, Hisataka Moriwaki, Kazuhide Yamamoto, Michio Sata, Shuntaro Obi, Shiro Miyayama, Yukinori Imai, Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update, Hepatology Research, 2012, 42, 6
  33. 33
    R. A. Pazo-Cid, M. Lanzuela, G. Esquerdo, J. L. Pérez-Gracia, A. Antón, G. Amigo, J. Martínez Trufero, A. L. García-Otín, P. Martín-Duque, Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC), Clinical and Translational Oncology, 2012, 14, 8, 564

    CrossRef

  34. 34
    Y-Y Shao, L-C Lu, Z-Z Lin, C Hsu, Y-C Shen, C-H Hsu, A-L Cheng, Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems, British Journal of Cancer, 2012, 107, 10, 1672

    CrossRef

  35. 35
    Yan Wang, Yi Chen, Ningling Ge, Lan Zhang, Xiaoying Xie, Jubo Zhang, Rongxin Chen, Yanhong Wang, Boheng Zhang, Jinglin Xia, Yuhong Gan, Zhenggang Ren, Shenglong Ye, Prognostic Significance of Alpha-fetoprotein Status in the Outcome of Hepatocellular Carcinoma after Treatment of Transarterial Chemoembolization, Annals of Surgical Oncology, 2012, 19, 11, 3540

    CrossRef

  36. 36
    Ines Martin-Padura, Paola Marighetti, Alice Agliano, Federico Colombo, Leyre Larzabal, Miriam Redrado, Anne-Marie Bleau, Celia Prior, Francesco Bertolini, Alfonso Calvo, Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts, Laboratory Investigation, 2012, 92, 7, 952

    CrossRef

  37. 37
    W.-Y. Kao, Y.-Y. Chiou, H.-H. Hung, C.-W. Su, Y.-H. Chou, J.-C. Wu, T.-I. Huo, Y.-H. Huang, W.-C. Wu, H.-C. Lin, S.-D. Lee, Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy, Clinical Radiology, 2012, 67, 5, 429

    CrossRef

  38. 38
    J. Wassermann, M. Bouattour, C. Dreyer, E. Raymond, S. Faivre, Thérapies ciblées dans le carcinome hépatocellulaire: indications et perspectives, Oncologie, 2012, 14, 3, 179

    CrossRef

  39. 39
    Nicola Personeni, Silvia Bozzarelli, Tiziana Pressiani, Lorenza Rimassa, Maria Chiara Tronconi, Francesco Sclafani, Carlo Carnaghi, Vittorio Pedicini, Laura Giordano, Armando Santoro, Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma, Journal of Hepatology, 2012, 57, 1, 101

    CrossRef

  40. 40
    Thomas Gamstätter, Arndt Weinmann, Simin Schadmand-Fischer, Pia R. Spies, Ina M. Niederle, Marcus Schuchmann, Peter R. Galle, Marcus-Alexander Wörns, AFP Measurement in Monitoring Treatment Response of Advanced Hepatocellular Carcinoma to Sorafenib: Case Report and Review of the Literature, Onkologie, 2011, 34, 10, 538

    CrossRef

  41. 41
    Geoffrey Y KU, Gilberto DE LIMA LOPES Jr, Alex Y CHANG, Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series, Asia-Pacific Journal of Clinical Oncology, 2011, 7, 2
  42. 42
    Sabine Irtan, Xavier Chopin-Laly, Maxime Ronot, Sandrine Faivre, Valérie Paradis, Jacques Belghiti, Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection, Liver International, 2011, 31, 5
  43. 43
    Tadashi Inuzuka, Hiroki Nishikawa, Akira Sekikawa, Haruhiko Takeda, Shinichiro Henmi, Azusa Sakamoto, Sumio Saito, Ryuichi Kita, Toru Kimura, Yukio Osaki, Masatoshi Kudo, Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case Report, Oncology, 2011, 81, s1, 152

    CrossRef

  44. 44
    Chao-Yu Hsu, Ying-Chun Shen, Chih-Wei Yu, Chiun Hsu, Fu-Chang Hu, Chih-Hung Hsu, Bang-Bin Chen, Shwu-Yuan Wei, Ann-Lii Cheng, Tiffany Ting-Fang Shih, Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil, Journal of Hepatology, 2011, 55, 4, 858

    CrossRef

  45. 45
    Teiji Kuzuya, Yasuhiro Asahina, Kaoru Tsuchiya, Keisuke Tanaka, Yuichiro Suzuki, Takahide Hoshioka, Shinji Tamaki, Tomoji Kato, Yutaka Yasui, Takahiro Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Namiki Izumi, Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma, Oncology, 2011, 81, 3-4, 251

    CrossRef

  46. 46
    Andrew X. Zhu, Dan G. Duda, Dushyant V. Sahani, Rakesh K. Jain, HCC and angiogenesis: possible targets and future directions, Nature Reviews Clinical Oncology, 2011, 8, 5, 292

    CrossRef

  47. 47
    Yu-Yun Shao, Zhong-Zhe Lin, Te-Jung Chen, Chiun Hsu, Ying-Chun Shen, Chih-Hung Hsu, Ann-Lii Cheng, High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy, Oncology, 2011, 81, 2, 98

    CrossRef

  48. 48
    A. Hollebecque, S. Cattan, O. Romano, G. Sergent, A. Mourad, A. Louvet, S. Dharancy, E. Boleslawski, S. Truant, F.-R. Pruvot, M. Hebbar, O. Ernst, P. Mathurin, Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score, Alimentary Pharmacology & Therapeutics, 2011, 34, 10